Biotech startups in Germany
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Tubulis | Munich | Series C | $400.6M | 2025-10-15 |
| Exciva | Heidelberg | Series B | $59.4M | 2026-01-20 |
| Seamless Therapeutics | Dresden | Seed | $12.6M | 2024-04-23 |
| NVision Quantum Technologies | Ulm | Series B | $38.0M | 2026-05-13 |
| Orbem | Munich | Series B | $64.6M | 2026-01-20 |
| Cellbox Solutions | Cologne | Series A | $1.7M | 2026-10-20 |
| Mindpeak | Hamburg | Series A | $15.3M | 2024-09-30 |
| Computomics | Tübingen | Series B | $7.3M | 2026-08-18 |
8 rows of the CSV in 5 of its 18 columns.
- The 265 biotech startups in Germany have raised $2.6B in total.
- 39 of them closed their most recent round in the last 12 months, $413.1M combined.
- The largest of those rounds is Orbem's $64.6M Series B, dated January 2026.
- The most recent is SRTD Biotech's $35.2M seed round on 9 November 2026.
- HTGF (High-Tech Gruenderfonds) is an investor in 72 of them, more than any other fund.
- Health care is the most common other sector, with 177 companies (67%).
- 33% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 1 to 10 employees (51% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 265| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Cellbox Solutions | Cellbox Solutions provides logistics solutions for the global biomedical industry. | Biotech | Cologne | Series A | $1.7M | 2026-10-20 | $15.3M | European Innovation Council, Fraunhofer Venture, CK Venture Capital | 11 to 50 | 2017 |
| Computomics | Computomics applies artificial intelligence to genomics data to advance agricultural solutions. | Artificial intelligence | Tübingen | Series B | $7.3M | 2026-08-18 | $10.0M | HTGF (High-Tech Gruenderfonds), VentureOut, European Innovation Council +2 | 11 to 50 | 2012 |
| smartbax | Smartbax develops multi-targeted antibacterial compounds that are potent against multi-drug resistant bacteria. | Biotech | Munich | Seed | $5.5M | 2026-06-30 | $7.5M | HTGF (High-Tech Gruenderfonds), Boehringer Ingelheim Venture Fund | 1 to 10 | 2021 |
| NVision Quantum Technologies | NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. | Biotech | Ulm | Series B | $38.0M | 2026-05-13 | $155.2M | Entrée Capital, European Commission, Playground Global +2 | 101 to 250 | 2015 |
| Tacalyx | Tacalyx develops cancer therapies that target tumor-associated carbohydrate antigens. | Biotech | Berlin | Seed | $12.9M | 2026-04-29 | $28.0M | HTGF (High-Tech Gruenderfonds), coparion, Kurma Partners +2 | 1 to 10 | 2019 |
| mbiomics | mbiomics is a biotechnology company. | Biotech | Munich | Series A | $12.0M | 2026-04-28 | $26.1M | HTGF (High-Tech Gruenderfonds), Bayern Kapital, MIG Capital | 11 to 50 | 2020 |
| Omegga GmbH | Omegga GmbH develops in-ovo sexing technology that identifies male chicks before hatching to prevent their killing. | Artificial intelligence | Munich | Seed | $11.7M | 2026-04-24 | $11.7M | EIC Accelerator, GETTY | 1 to 10 | 2022 |
| Cellbricks Therapeutics | Cellbricks Therapeutics is a biotech company developing methods for replacing tissue and organs. | Biotech | Berlin | Seed | $8.1M | 2026-03-25 | $11.6M | b.value AG, Brooks Hill Partners | 11 to 50 | 2016 |
| Kupando | Kupando is a biopharmaceutical company developing agonists that stimulate innate immunity. | Biotech | Schönefeld | Series A | $11.5M | 2026-03-18 | $24.0M | HTGF (High-Tech Gruenderfonds), Brandenburg Kapital, Remiges Ventures +2 | 1 to 10 | 2018 |
| Innocent Meat | Innocent Meat provides plug-and-play technology that converts meat producers into cell-based producers. | Biotech | Rostock | Seed | $7.1M | 2026-01-22 | $11.0M | Big Idea Ventures, GENIUS Venture Capital | 1 to 10 | 2020 |
| Orbem | Orbem provides AI-powered imaging and analytics for non-invasive biological insights. | Artificial intelligence | Munich | Series B | $64.6M | 2026-01-20 | $106.5M | European Innovation Council, Possible Ventures, 83North +1 | 101 to 250 | 2019 |
| Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| 4TEEN4 Pharmaceuticals | 4TEEN4 Pharmaceuticals develops therapies and biomarkers for diagnosing, predicting, and treating circulatory shock. | Biotech | Hennigsdorf | Series C | $36.1M | 2025-11-13 | $95.9M | Wellington Partners, Brandenburg Kapital, HBM Healthcare Investments +1 | 11 to 50 | 2013 |
| Tubulis | Tubulis generates antibody-drug conjugates with unique properties for solid tumor indications. | Biotech | Munich | Series C | $400.6M | 2025-10-15 | $616.9M | HTGF (High-Tech Gruenderfonds), Bayern Kapital, Seventure Partners +1 | 51 to 100 | 2012 |
| Clinomic | Clinomic is a medical AI company focused on critical care. | Artificial intelligence | Aachen | Series B | $25.3M | 2025-04-08 | $54.6M | German Federal Ministry of Research, Technology and Space | 51 to 100 | 2019 |
| UniteLabs | UniteLabs provides an automation operating system for laboratories. | Biotech | Munich | Pre-seed | $3.1M | 2025-04-03 | $3.1M | Venture Kick | 11 to 50 | 2022 |
| Mindpeak | Mindpeak develops AI-based diagnostic software that detects, quantifies, and classifies cancer. | Artificial intelligence | Hamburg | Series A | $15.3M | 2024-09-30 | European Innovation Council, EIC Accelerator, Nina Capital +2 | 11 to 50 | 2018 | |
| Qualifyze | Qualifyze provides global quality audit and site risk management solutions for life sciences companies. | Biotech | Frankfurt | Series B | $54.0M | 2024-09-10 | Insight Partners, APX, HV Capital +2 | 101 to 250 | 2019 | |
| Aurora Life Science | Aurora Life Science develops AI, mobile app, and digital health solutions. | Biotech | Darmstadt | Pre-seed | $903K | 2024-08-14 | BM H Beteiligungs-Managementgesellschaft Hessen | 1 to 10 | 2019 | |
| PL BioScience | PL BioScience delivers 2D and 3D cell culture solutions based on human Platelet Lysate. | Biotech | Aachen | Series A | $8.5M | 2024-08-08 | $13.0M | TechVision Fund, better ventures, Brightlands Venture Partners +1 | 11 to 50 | 2015 |
| Lignopure GmbH | Lignopure GmbH supplies plant-based lignin ingredients for high-value markets. | Biotech | Hamburg | Seed | $2.6M | 2024-07-17 | HTGF (High-Tech Gruenderfonds), NBank Capital, Raakwark Kaptaal +1 | 11 to 50 | 2019 | |
| CatalYm | CatalYm develops immunotherapies to treat cancer. | Biotech | Planegg | Series D | $150.0M | 2024-07-16 | $260.9M | Bayern Kapital, Forbion Capital Partners, Novartis Venture Fund +1 | 11 to 50 | 2016 |
| Cultimate Foods | Cultimate Foods is a cellular agriculture company. | Biotech | Berlin | Seed | $2.5M | 2024-04-23 | HTGF (High-Tech Gruenderfonds), MassChallenge Switzerland, Big Idea Ventures +2 | 1 to 10 | 2022 | |
| FundaMental Pharma | FundaMental Pharma is a neuroscience company with preclinical-stage drug candidates. | Biotech | Heidelberg | Seed | $2.9M | 2024-04-11 | $13.3M | HTGF (High-Tech Gruenderfonds), Novartis Venture Fund, coparion +2 | 1 to 10 | 2016 |
| traceless materials | traceless materials develops circular bioeconomy alternatives to conventional plastics and bioplastics. | Biotech | Hamburg | Series A | $38.8M | 2023-09-25 | HTGF (High-Tech Gruenderfonds), European Innovation Council, Planet A Ventures +2 | 51 to 100 | 2020 | |
| Transimmune | Transimmune develops dendritic cell therapies based on its biological production of dendritic cells. | Biotech | Düsseldorf | Seed | $5.0M | 2023-09-20 | Bill & Melinda Gates Foundation | 1 to 10 | 2012 | |
| DNTOX | DNTOX provides an in vitro testing battery for assessing the safety of chemicals. | Biotech | Düsseldorf | Seed | $1.5M | 2023-06-14 | HTGF (High-Tech Gruenderfonds), AQAL Integral Investing, Bool Capital | 1 to 10 | 2022 | |
| LabDAO | LabDAO is a research organization working to advance computational life sciences. | Biotech | Berlin | Seed | $3.6M | 2023-05-23 | Village Global, Orange DAO, Seed Club Ventures | 1,001 to 5,000 | 2022 | |
| iThera Medical | iThera Medical develops proprietary MSOT imaging technology for preclinical and clinical applications. | Biotech | Munich | Series D | $13.8M | 2022-12-21 | $42.3M | European Innovation Council, Bayern Kapital, German Federal Ministry of Research, Technology and Space +1 | 11 to 50 | 2010 |
| Resolve BioSciences | Resolve BioSciences conducts biotechnology research in molecular cartography. | Biotech | Düsseldorf | Series B | $71.0M | 2022-10-24 | $95.0M | HTGF (High-Tech Gruenderfonds), EDBI, NRW.BANK +2 | 51 to 100 | 2020 |
Table 1. Biotech startups in Germany: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 265.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Orbem | Orbem provides AI-powered imaging and analytics for non-invasive biological insights. | Artificial intelligence | Munich | Series B | $64.6M | 2026-01-20 | $106.5M | European Innovation Council, Possible Ventures, 83North +1 | 101 to 250 | 2019 |
| 2 | Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| 3 | NVision Quantum Technologies | NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. | Biotech | Ulm | Series B | $38.0M | 2026-05-13 | $155.2M | Entrée Capital, European Commission, Playground Global +2 | 101 to 250 | 2015 |
| 4 | Tacalyx | Tacalyx develops cancer therapies that target tumor-associated carbohydrate antigens. | Biotech | Berlin | Seed | $12.9M | 2026-04-29 | $28.0M | HTGF (High-Tech Gruenderfonds), coparion, Kurma Partners +2 | 1 to 10 | 2019 |
| 5 | mbiomics | mbiomics is a biotechnology company. | Biotech | Munich | Series A | $12.0M | 2026-04-28 | $26.1M | HTGF (High-Tech Gruenderfonds), Bayern Kapital, MIG Capital | 11 to 50 | 2020 |
| 6 | Omegga GmbH | Omegga GmbH develops in-ovo sexing technology that identifies male chicks before hatching to prevent their killing. | Artificial intelligence | Munich | Seed | $11.7M | 2026-04-24 | $11.7M | EIC Accelerator, GETTY | 1 to 10 | 2022 |
| 7 | Kupando | Kupando is a biopharmaceutical company developing agonists that stimulate innate immunity. | Biotech | Schönefeld | Series A | $11.5M | 2026-03-18 | $24.0M | HTGF (High-Tech Gruenderfonds), Brandenburg Kapital, Remiges Ventures +2 | 1 to 10 | 2018 |
| 8 | Cellbricks Therapeutics | Cellbricks Therapeutics is a biotech company developing methods for replacing tissue and organs. | Biotech | Berlin | Seed | $8.1M | 2026-03-25 | $11.6M | b.value AG, Brooks Hill Partners | 11 to 50 | 2016 |
| 9 | Computomics | Computomics applies artificial intelligence to genomics data to advance agricultural solutions. | Artificial intelligence | Tübingen | Series B | $7.3M | 2026-08-18 | $10.0M | HTGF (High-Tech Gruenderfonds), VentureOut, European Innovation Council +2 | 11 to 50 | 2012 |
| 10 | Innocent Meat | Innocent Meat provides plug-and-play technology that converts meat producers into cell-based producers. | Biotech | Rostock | Seed | $7.1M | 2026-01-22 | $11.0M | Big Idea Ventures, GENIUS Venture Capital | 1 to 10 | 2020 |
Table 2. Biotech startups in Germany: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 72 | 27% | 5 | Computomics, smartbax, Tacalyx |
| 2 | KfW | Government investment office | Frankfurt, Germany | 21 | 8% | ||
| 3 | Bayern Kapital | Venture capital firm | Landshut, Germany | 13 | 5% | 1 | mbiomics |
| 4 | European Innovation Council | Startup accelerator | Brussels, Belgium | 8 | 3% | 3 | Cellbox Solutions, Computomics, Orbem |
| 5 | NRW.BANK | Government investment office | Düsseldorf, Germany | 7 | 3% | ||
| 6 | Andera Partners | Private equity firm | Paris, France | 6 | 2% | 1 | Exciva |
| 7 | Wellington Partners | Venture capital firm | Munich, Germany | 6 | 2% | ||
| 8 | German Federal Ministry of Research, Technology and Space | Government investment office | Bonn, Germany | 6 | 2% | 1 | NVision Quantum Technologies |
| 9 | Fraunhofer Venture | Venture capital firm | Munich, Germany | 6 | 2% | 1 | Cellbox Solutions |
| 10 | MIG Capital | Venture capital firm | Munich, Germany | 6 | 2% | 1 | mbiomics |
| 11 | Boehringer Ingelheim Venture Fund | Corporate venture arm | Ingelheim Am Rhein, Germany | 6 | 2% | 2 | smartbax, Tacalyx |
| 12 | LBBW VC | Corporate venture arm | Stuttgart, Germany | 5 | 2% | 1 | Exciva |
| 13 | b.value AG | Venture capital firm | Dortmund, Germany | 5 | 2% | 1 | Cellbricks Therapeutics |
| 14 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 5 | 2% | ||
| 15 | EMBL Ventures | Venture capital firm | Heidelberg, Germany | 5 | 2% |
Table 3. Biotech startups in Germany: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 177 | 67% | $2.4B |
| Software | 47 | 18% | $241.3M |
| Artificial intelligence | 29 | 11% | $203.8M |
| Hardware | 11 | 4% | $135.2M |
| Education | 4 | 2% | |
| Fintech | 2 | 1% | $2.2M |
| Energy | 2 | 1% | $655K |
| Cybersecurity | 1 | 0% |
Table 4. Biotech startups in Germany by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. Biotech startups in Germany by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 6. Biotech startups in Germany by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 3% | $35.2M |
| October 2026 | 2 | 5% | $1.7M |
| September 2026 | 7 | 18% | $16.5M |
| August 2026 | 3 | 8% | $14.3M |
| June 2026 | 2 | 5% | $55.5M |
| May 2026 | 4 | 10% | $45.2M |
| April 2026 | 7 | 18% | $43.9M |
| March 2026 | 5 | 13% | $41.3M |
| January 2026 | 5 | 13% | $133.7M |
| December 2025 | 2 | 5% | $25.9M |
| November 2025 | 1 | 3% |
Table 7. Biotech startups in Germany: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 36 | 14% | $387.2M |
| 2025 | 23 | 9% | $542.7M |
| 2024 | 32 | 12% | $381.0M |
| 2023 | 15 | 6% | $94.6M |
| 2022 | 25 | 9% | $143.0M |
| 2021 | 17 | 6% | $472.5M |
Table 8. Biotech startups in Germany by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 29 | 11% |
| 2020 to 2022 | 57 | 22% |
| 2015 to 2019 | 70 | 27% |
| 2010 to 2014 | 47 | 18% |
| Before 2010 | 59 | 23% |
Table 9. Biotech startups in Germany by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 133 | 51% |
| 11 to 50 | 104 | 40% |
| 51 to 100 | 13 | 5% |
| 101 to 250 | 7 | 3% |
| 251 to 500 | 1 | 0% |
| 501 to 1,000 | 2 | 1% |
| 1,001 to 5,000 | 2 | 1% |
| 10,001 or more | 1 | 0% |
Table 10. Biotech startups in Germany by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Germany. On 16 November 2026 that is 265 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 265 rows: 97 have no round amount, 0 no city and 120 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Germany are on the list?
- 265, in the file dated 16 November 2026. 39 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 265 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.